ReviewStem cell reviews and reports2022
Iron Oxide Nanoparticles in Mesenchymal Stem Cell Detection and Therapy.
Review in Stem cell reviews and reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- The role of stem cells in the pharmacological assessment of nanoparticles.Journal of pharmaceutical analysis · 2026Review
- Stem Cell-Based Strategies for Fibrotic and Neurogenic Bladder Disorders: Current Evidence, Translational Challenges, and Future Directions.Current issues in molecular biology · 2026Review
- Iron-quercetin nanocomplex preconditioning reprograms the mesenchymal stem cell secretome to drive angiogenic, fibroblast and immunoregulatory wound repair.Regenerative biomaterials · 2026Article
- Superparamagnetic iron oxide nanoparticles in clinical applications: current status and future perspectives.EBioMedicine · 2025Review
- Functionalized mesenchymal stem cells for enhanced bone regeneration: advances and challenges.Stem cell research & therapy · 2025Review
- Boosting the velocity detection limit of 3D single-cell tracking time-lapse MRI by balanced SSFP imaging.Magnetic resonance in medicine · 2025Article
- Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies.Signal transduction and targeted therapy · 2025Review
- Formation and evaluation of docetaxel and triptolide polymer micelles for anti-cancer activity.Nanomedicine (London, England) · 2025Article
- Development of Iron Oxide Nanochains as a Sensitive Magnetic Particle Imaging Tracer for Cancer Detection.ACS applied materials & interfaces · 2025Article
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Biomedical Application Prospects of Gadolinium Oxide Nanoparticles for Regenerative Medicine.Pharmaceutics · 2024Article
- The Role of Mitochondrial Homeostasis in Mesenchymal Stem Cell Therapy-Potential Implications in the Treatment of Osteogenesis Imperfecta.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Current Challenges in Microcapsule Designs and Microencapsulation Processes: A Review.ACS applied materials & interfaces · 2024Review
- Geometry and Surface Area Optimization in Iron Oxide Nanoparticles for Enhanced Magnetic Properties.ACS omega · 2024Article
- Precision Nanomedicine with Bio-Inspired Nanosystems: Recent Trends and Challenges in Mesenchymal Stem Cells Membrane-Coated Bioengineered Nanocarriers in Targeted Nanotherapeutics.Journal of xenobiotics · 2024Review
- Recent advances of nanoparticles on bone tissue engineering and bone cells.Nanoscale advances · 2024Review
- Effects of royal jelly on the antisenescence, mitochondrial viability and osteogenic differentiation capacity of umbilical cord-derived mesenchymal stem cells.Histochemistry and cell biology · 2024Article
- Iron-Related Genes and Proteins in Mesenchymal Stem Cell Detection and Therapy.Stem cell reviews and reports · 2023Review
- MSC based gene delivery methods and strategies improve the therapeutic efficacy of neurological diseases.Bioactive materials · 2023Review
- Metal-based nanomaterials and nanocomposites as promising frontier in cancer chemotherapy.MedComm · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) exhibit regenerative and reparative properties. However, most MSC-related studies remain to be translated for regular clinical usage, partly due to challenges in pre-transplantation cell labelling and post-transplantation cell tracking. Amidst this, there are growing concerns over the toxicity of commonly used gadolinium-based contrast agents that mediate in-vivo cell detection via MRI. This urges to search for equally effective but less toxic alternatives that would facilitate and enhance MSC detection post-administration and provide therapeutic benefits in-vivo. MSCs labelled with iron oxide nanoparticles (IONPs) have shown promising results in-vitro and in-vivo. Thus, it would be useful to revisit these studies before inventing new labelling approaches. Aiming to inform regenerative medicine and augment clinical applications of IONP-labelled MSCs, this review collates and critically evaluates the utility of IONPs in enhancing MSC detection and therapeutics. It explains the rationale, principle, and advantages of labelling MSCs with IONPs, and describes IONP-induced intracellular alterations and consequent cellular manifestations. By exemplifying clinical pathologies, it examines contextual in-vitro, animal, and clinical studies that used IONP-labelled bone marrow-, umbilical cord-, adipose tissue- and dental pulp-derived MSCs. It compiles and discusses studies involving MSC-labelling of IONPs in combinations with carbohydrates (Venofer, ferumoxytol, dextran, glucosamine), non-carbohydrate polymers [poly(L-lysine), poly(lactide-co-glycolide), poly(L-lactide), polydopamine], elements (ruthenium, selenium, gold, zinc), compounds/stains (silica, polyethylene glycol, fluorophore, rhodamine B, DAPI, Prussian blue), DNA, Fibroblast growth Factor-2 and the drug doxorubicin. Furthermore, IONP-labelling of MSC exosomes is reviewed. Also, limitations of IONP-labelling are addressed and methods of tackling those challenges are suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.